Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant intent anti-PD-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy.

The oncologist·2026
Same author

Prognostic Factors in Primary Head and Neck Cutaneous Squamous Cell Carcinoma: A Large-Scale, Multi-Institutional Competing-Risks Analysis.

Journal of surgical oncology·2026
Same author

Collaboration Between Mohs and Surgical Subspecialists in the Treatment of Advanced Nonmelanoma Skin Cancer.

Head & neck·2026
Same author

ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence.

JAMA dermatology·2026
Same author

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

JAMA dermatology·2026
Same author

Liquid Biopsy in Cutaneous Oncology: Current Practice and Future Directions.

Journal of the American Academy of Dermatology·2026

Related Experiment Videos

Low Dose Long-Term Capecitabine for Refractory Field Cancerization: A Retrospective Cohort Study.

Haley Neff1, Caroline Mortelliti1, Brenda Solomon1

  • 1Department of Dermatology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA.

Journal of the American Academy of Dermatology
|June 27, 2026
PubMed
Summary

Long-term, low-dose capecitabine effectively reduced keratinocyte carcinoma surgeries in patients with field cancerization. Most patients reported improved skin lesions and preferred this treatment over alternatives.

Keywords:
5-fluorouracilacitretincapecitabinechemoprophylaxiscutaneous oncologyfield cancerizationnicotinamide

Related Experiment Videos

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Topical-refractory cutaneous field cancerization presents significant management challenges and patient distress.
  • Effective therapeutic strategies for this condition are critically needed.

Purpose of the Study:

  • To evaluate the long-term efficacy, toxicity, and patient satisfaction of low-dose capecitabine for cutaneous field cancerization.
  • To assess the impact of capecitabine on the number of keratinocyte carcinoma surgeries.

Main Methods:

  • A retrospective cohort and survey study was conducted at a single institution.
  • Patients received long-term, low-dose capecitabine for cutaneous field cancerization.
  • Wilcoxon matched-pairs signed-rank test compared annual keratinocyte carcinoma surgeries pre- and post-treatment.

Main Results:

  • Mean keratinocyte carcinoma surgeries decreased significantly by year 2 (73% reduction, p=0.02).
  • Two patients (10%) discontinued treatment due to toxicity.
  • A majority of surveyed patients (75%) reported moderate to significant improvement in skin lesions, with 83.3% preferring capecitabine.

Conclusions:

  • Long-term, low-dose capecitabine demonstrates efficacy in reducing keratinocyte carcinoma surgeries for field cancerization.
  • The treatment is generally well-tolerated and associated with high patient satisfaction.
  • Capecitabine represents a viable and preferred treatment option for managing refractory cutaneous field cancerization.